Does One Small Biotech Company Hold The Key To Conquering Two Of Mankind’s Most Feared Diseases?


The smart money seems to think so.

San Diego-based clinical-stage biotechnology company INmune Bio (NASDAQ:INMB) has three promising therapies now in clinical trial. Two of these target cancers; the other Alzheimer’s.

All three of the company’s therapies are designed to reprogram the body’s immune system to help it defeat these diseases. And while other companies are spending billions on therapies to harness the immune system, INmune Bio (INMB) approach is very different.

The Other Side Of The System

To put it simply, INmune Bio is looking where nobody else is. It’s focused on the other side of the immune system – the innate immune side.

Most people don’t realize that the human body’s immune system has two sides – essentially two immune systems. The adaptive side responds to foreign substances that enter the body; the innate side of the system deals with bad things that are already there.

And because many cancers develop from pre-cancerous cells that are created by the body, the adaptive immune system gives them a pass. Fortunately, the innate system doesn’t.

Its cells seek out and kill these abnormal cells. Which is why they’re called
Natural Killer Cells.

But sometimes these Natural Killer can’t do their job because cancer cells have the uncanny ability to make themselves virtually invisible. Especially those cancer cells left in the body after treatment. INmune Bio solution to the problem is a new product called INKmune™
INKmune™ programs the NK cells to identify these cloaked cancer cells and kill them. Which makes INKmune unlike any other cancer therapy in the world.

INKmune™ is currently approved for Phase 1 clinical trials in Great Britain. Once these results are accepted, the company plans Phase 2 trials in the United States.

As much of a breakthrough as INKmune™ promises to be, it’s not the only cancer weapon in INmune Bio’s arsenal. Of equal importance is …


INBO3 is a protein biologic that works by inhibiting the activities of another set of cells most people never heard of, the Myeloid-Derived Suppressor Cells or MDSC. These cells do their damage by creating a shield around the patient’s tumor so the body’s immune system can’t get at it.

INmune Bio (INMB) their INBO3 strips

away this shield so NK cells can attack the tumor. That gives other treatments a much better chance of being effective. And unlike earlier therapies, INBO3 doesn’t totally suppress the immune system which could make the cancer worse. What’s more, it can be combined with other therapies such as INKmune™ to enhance the cancer-fighting abilities of both.

In animal studies, those treated with INBO3 had smaller and fewer tumors, resulting in increased survival. The therapy is now in Phase 1 clinical trial with patients with advanced solid tumors.

INBO3 is part of a class of drugs called checkpoint inhibitors which is said to be a billion dollar market in the US alone. Other drugs in this class only work in 25% of cancer patients. With the increased efficacy of INBO3, INmune Bio believes it can help many more
patients and – not coincidentally – dominate the market.

INmune Bio’s cancer-fighting therapies and its approach to the disease have been subject to rigorous peer review and the results published in more than 50 scientific publications.

But INmune Bio (INMB) doesn’t stop at cancer. It’s also going after Alzheimer’s

A Different Approach To Alzheimer’s

Over 50 million people around the world suffer from Alzheimer’s, a number that continues to grow with the aging global population. At present, no cure exists.

Attempts at developing one have so far centered around treating Alzheimer’s as a neurology or brain disease. So far these attempts have been unsuccessful. Not surprisingly, INmune Bio is taking a decidedly different route. The company’s strategy is to attack Alzheimer’s as an immunologic disease.

The neurological approach holds that the disease begins with a dysfunction of the brain’s neurons or nerve cells and that inflammation is the result of the diseased neurons. INmune Bio believes that the damage to neurons is the result of the inflammation – not its cause.
This inflammation serves to “short circuit” much of the brain’s activity leading to cognitive decline, dementia, and other behavioral symptoms.

INmune Bio awarded a $1million grant for its Alzheimer’s treatment therapy

Consequently, INmune Bio’s new Alzheimer’s therapy, Xpro1595, targets the inflammatory changes in the brain. INmune Bio’s scientists say that once the inflammation is brought under control, cells begin to normalize themselves and the disease process is not only halted but shows signs of reversing.

What’s more, XPro1595 is expected to ameliorate the often-devastating symptoms of Alzheimer’s such as depression and anxiety.

In recognition of INmune Bio’s revolutionary approach, the Alzheimer’s Association awarded the company a million-dollar “Part the Cloud to RESCUE” grant.

The company plans to use the grant to advance XPro1595 in a Phase 1 trial expected to start mid-year.

Through The Roof?

Should INmune Bio (NASDAQ:INMB) succeed in just one of its therapies, that’s where its stock would likely go. In biotech, it’s similar to when an oil company makes a discovery. The stocks go BIG.
But because stock in biotech companies can move on data alone, major movement could occur on the outcome of one of INmune Bio’s clinical trials for its therapies. And those are right around the corner.

How other micro-cap biotechs are faring



Readouts of Phase 1 clinical trial results for INBO3 are expected by the end of March. The second half of 2019 Phase 1 readouts on INKmune™ are due soon. Enrollment in Phase 2 trials for INBO3 is scheduled for later this year. And enrollment in Phase 1 trials for XPR01595 is also set for later this year.

An Acquisition Magnet?

INmune Bio (NASDAQ:INMB) would also become a prime target for a buy out. Small, agile biotech companies that are developing disruptive technologies like INmune Bio are always targets for big pharma.

Big pharmaceutical companies don’t innovate – they acquire.

Xencor (XNCR), a pioneer in antibody drugs and INmune Bio’s largest shareholder, has an option to buy another 10% of the company could likely opt for the rest of it. Unless, of course, another deep-pocketed, big pharma company gets there first.

Billion Dollar Buyouts

There’ve been a lot of those in the immune-oncology space lately.

  • – In 2017, Gilead (GILD) bought Kite Pharma (KITE) in a $11.9 Billion deal.
  • Celgene (CELG) acquired Juno (JUNO) for $9 Billion last year.
  • – This year, Bristol-Myers Squibb (BMY) bought Celgene in a $74 Billion deal.
  • And Eli Lilly (LLY) paid close to $8 Billion for Loxo Oncology (LOXO.)

All of the companies bought were developing therapies and were acquired Pre-FDA approval. And every one was working along adaptive immune-oncology lines. Which, so far, haven’t worked.

Just imagine what big pharma would pay for a biotech with a therapy that did?

All of which in our opinion, makes INmune Bio (INMB) an immediate and unequivocal “buy.” But you might want to act fast. Before big pharma gets there.

More Than Making Money

This is one of those rare cases where there’s something even more important than that…

For if even one of the company’s new products proves safe and effective, the treatment of cancer or Alzheimer’s and the lives of millions of people would be forever changed. And the world would be changed … for the better.

If you’d like to be a part of that, while making a lot of money, we’d suggest you start researching INmune Bio now!

For more information on INmuneBio’s (INMB), visit the company’s website and corporate presentation:

Disclosure: The information, opinions and analysis contained in this report are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security. Past gains are not representative of future gains. Prime IR LLC has been and will be compensated for distribution of its opinions and publicly available information regarding the companies reported in this investment opinion article by INmune Bio inc. as follows:
$10,000 of INmune Bio Inc. $100,000 online media buying budget wired to Prime IR LLC.
Prime IR’s affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event these shares rise in value. Prime IR will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

The opinions contained herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. Prime IR LLC is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at Investing in securities is speculative and carries risk. Please visit For more details.